AR118957A1 - CD19-BINDING MOLECULES AND USES THEREOF - Google Patents
CD19-BINDING MOLECULES AND USES THEREOFInfo
- Publication number
- AR118957A1 AR118957A1 ARP200101412A ARP200101412A AR118957A1 AR 118957 A1 AR118957 A1 AR 118957A1 AR P200101412 A ARP200101412 A AR P200101412A AR P200101412 A ARP200101412 A AR P200101412A AR 118957 A1 AR118957 A1 AR 118957A1
- Authority
- AR
- Argentina
- Prior art keywords
- binding molecules
- conjugates
- host cells
- further provides
- methods
- Prior art date
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente divulgación proporciona moléculas de unión a CD19 que se unen específicamente a CD19, incluyendo moléculas de unión monoespecíficas, biespecíficas y triespecíficas, conjugados que comprenden las moléculas de unión a CD19, y composiciones farmacéuticas que comprenden las moléculas de unión a CD19 y los conjugados. La divulgación proporciona además métodos de uso de las moléculas de unión a C19 para tratar enfermedades y trastornos asociados con la expresión de CD19. La divulgación proporciona aún adicionalmente células huésped recombinantes modificadas por ingeniería genética para expresar las moléculas de unión a CD19 y métodos de producción de las moléculas de unión a CD19 mediante cultivo de las células huésped en condiciones en las que las moléculas de unión a CD19 se expresan.The present disclosure provides CD19-binding molecules that specifically bind to CD19, including monospecific, bispecific, and trispecific binding molecules, conjugates comprising the CD19-binding molecules, and pharmaceutical compositions comprising the CD19-binding molecules and conjugates. . The disclosure further provides methods of using the C19-binding molecules to treat diseases and disorders associated with CD19 expression. The disclosure still further provides recombinant host cells genetically engineered to express the CD19-binding molecules and methods of producing the CD19-binding molecules by culturing the host cells under conditions in which the CD19-binding molecules are expressed. .
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962850901P | 2019-05-21 | 2019-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118957A1 true AR118957A1 (en) | 2021-11-10 |
Family
ID=80053365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101412A AR118957A1 (en) | 2019-05-21 | 2020-05-19 | CD19-BINDING MOLECULES AND USES THEREOF |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR118957A1 (en) |
-
2020
- 2020-05-19 AR ARP200101412A patent/AR118957A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003050A1 (en) | CD19 binding molecules and uses thereof | |
| CL2022003788A1 (en) | Binding molecules against bcma and uses thereof | |
| MX2020009366A (en) | Anti-cd73 antibodies and uses thereof. | |
| CO2018012415A2 (en) | Specific binding proteins and uses thereof | |
| UY38242A (en) | ANTI-CD33 ANTIBODIES, ANTI-CD33 / ANTI-CD3 BIOSPECIFIC ANTIBODIES AND USES OF THEM | |
| AR066198A1 (en) | ANTI IGE APOPTOTIC ANTIBODIES | |
| MX2021013336A (en) | ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR CD19. | |
| BR112019011450A2 (en) | modified natural killer cells and their use | |
| BR112015019603A2 (en) | ISOLATED NUCLEIC ACID MOLECULES, ISOLATED POLYPEPTIDE MOLECULES, ISOLATED CAR MOLECULES, ANTI-EGFRVIII BINDING DOMAIN, VECTOR, CELL AND USE OF AN EFFECTIVE AMOUNT THEREOF, AND METHODS FOR PRODUCING A CELL AND PRODUCING A POPULATION OF CELLS MODIFIED BY RNA | |
| CO2018012513A2 (en) | Antibodies | |
| ECSP14001260A (en) | BI-SPECIFIC IMMUNOLIGANTS TARGETED AGAINST TNF AND IL-17 CROSS REFERENCE TO RELATED REQUESTS | |
| ECSP14013132A (en) | ANTI-PSGL-1 ANTIBODIES AND USES OF THE SAME | |
| AR093394A1 (en) | SPECIFIC ANTIBODIES OF THE GROWTH FACTOR B DERIVED FROM PLATES (PDGF-B), COMPOSITIONS AND USES OF THESE | |
| CL2021003151A1 (en) | Compositions and methods for the selective regulation of genes | |
| PT3927370T (en) | METHODS FOR PRODUCING AUTOLOGOUS T CELLS TO TREAT CANCERS AND COMPOSITIONS THEREOF | |
| CL2019000999A1 (en) | Antibodies that bind to the envelope protein of the Zika virus and their uses. | |
| UY37630A (en) | PHARMACEUTICAL COMBINATION, KIT, GUEST CELL THAT PRODUCES IT AND ITS USE IN METHODS FOR CANCER TREATMENT | |
| MX2023009882A (en) | Anti-muc1-c antibodies and car-t structures. | |
| MX2020001287A (en) | Braf-specific tcrs and uses thereof. | |
| MX2023005353A (en) | Cd19 binding molecules and uses thereof. | |
| CL2021002838A1 (en) | Conjugated anti-bcma antibody, compositions comprising the same, and methods of making and using the same. | |
| AR118957A1 (en) | CD19-BINDING MOLECULES AND USES THEREOF | |
| AR115451A1 (en) | BINDING MOLECULES AGAINST BCMA AND USES OF THEM | |
| EA202193180A1 (en) | CD19-BINDING MOLECULES AND THEIR APPLICATIONS | |
| UY36922A (en) | ASGR INHIBITORS |